Showing 3441-3450 of 5381 results for "".
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Survey Reveals Clinician Views on CHE's Impact on Quality of Lifehttps://practicaldermatology.com/news/Survey-Reveals-Clinician-Views-CHEs-Impact-Quality-Life/2474228/Ninety-five percent of US dermatology clinicians surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, according to the second phase of a survey sponsored by LEO Pharma Inc., the company announced in a press release. The survey, w
- Increased Cost Diminishes Sunscreen Use: Reporthttps://practicaldermatology.com/news/cost-influences-sunscreen-use-raising-skin-cancer-risk-study-shows/2474206/Patients use less sunscreen when it’s more expensive, according to a brief report in the Journal of the American Academy of Dermatology. Researchers from the University of California, Sa
- Review Unpacks Safety Data in Psoriasis Trialshttps://practicaldermatology.com/news/review-unpacks-safety-data-in-psoriasis-trials/2474174/While clinical trials frequently emphasize efficacy, safety data often remain inconsistently analyzed and underreported, according to the authors of a new review in the Journal of Clinical and Aesthetic Dermatology.
- CAB Gel Reduces Lesions and Preserves Skin Tone in Skin of Colorhttps://practicaldermatology.com/news/cab-gel-reduces-lesions-and-preserves-skin-tone-in-skin-of-color/2474010/A post hoc analysis of pooled Phase 2 and Phase 3 clinical trial data suggests that clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is effective and well tolerated for the treatment of moderate to severe acne in Black patients.
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- No Link Between PCSK9 Inhibitors and Vitiligo Risk: Studyhttps://practicaldermatology.com/news/analysis-no-link-between-pcsk9-inhibitors-and-vitiligo-risk/2471859/New research published in the Journal of Investigative Dermatology shows no evidence linking PCSK9 inhibitors to an increased risk of vitiligo. Researchers exploring whether inhibiting PCSK9